Header Logo

Connection

John Zajecka to Humans

Back to Details
This is a "connection" page, showing publications John Zajecka has written about Humans.
John Zajecka
Connection Strength
0.640
Humans
  1. Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series. J Clin Psychiatry. 2023 02 01; 84(2).
    View in: PubMed
    Score: 0.046
  2. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. Am J Psychiatry. 2017 07 01; 174(7):640-648.
    View in: PubMed
    Score: 0.030
  3. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60.
    View in: PubMed
    Score: 0.029
  4. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013 Apr; 74(4):407-14.
    View in: PubMed
    Score: 0.023
  5. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013; 74 Suppl 2:9-13.
    View in: PubMed
    Score: 0.023
  6. Evidence for the use of l-methylfolate combined with antidepressants in MDD. J Clin Psychiatry. 2011 Aug; 72(8):e25.
    View in: PubMed
    Score: 0.021
  7. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44.
    View in: PubMed
    Score: 0.019
  8. Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases. J Clin Psychiatry. 2008 Jun; 69(6):1016-8.
    View in: PubMed
    Score: 0.017
  9. Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry. 2007; 68 Suppl 10:23-7.
    View in: PubMed
    Score: 0.015
  10. Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder. CNS Spectr. 2006 Nov; 11(11 Suppl 13):1-11; discussion 12-3; quiz 14-6.
    View in: PubMed
    Score: 0.015
  11. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
    View in: PubMed
    Score: 0.012
  12. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002 Dec; 63(12):1148-55.
    View in: PubMed
    Score: 0.011
  13. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry. 2002 Aug; 63(8):709-16.
    View in: PubMed
    Score: 0.011
  14. Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression. Neuromodulation. 2022 Apr; 25(3):316-326.
    View in: PubMed
    Score: 0.011
  15. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
    View in: PubMed
    Score: 0.011
  16. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3:35-43.
    View in: PubMed
    Score: 0.010
  17. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov; 157(11):1873-5.
    View in: PubMed
    Score: 0.010
  18. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000 Sep; 59 Suppl 1:S39-S56.
    View in: PubMed
    Score: 0.010
  19. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
    View in: PubMed
    Score: 0.009
  20. Construct validity of life chart functioning scales for use in naturalistic studies of bipolar disorder. J Psychiatr Res. 2000 May-Jun; 34(3):187-92.
    View in: PubMed
    Score: 0.009
  21. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245.
    View in: PubMed
    Score: 0.009
  22. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
    View in: PubMed
    Score: 0.009
  23. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000; 61 Suppl 2:20-5.
    View in: PubMed
    Score: 0.009
  24. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 09 01; 76(9):893-903.
    View in: PubMed
    Score: 0.009
  25. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
    View in: PubMed
    Score: 0.009
  26. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998 Jun; 18(3):193-7.
    View in: PubMed
    Score: 0.008
  27. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997 Jul; 58(7):291-7.
    View in: PubMed
    Score: 0.008
  28. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry. 1997; 58 Suppl 3:9-13; discussion 14-5.
    View in: PubMed
    Score: 0.007
  29. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997; 58 Suppl 7:5-10.
    View in: PubMed
    Score: 0.007
  30. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997; 58 Suppl 7:23-7.
    View in: PubMed
    Score: 0.007
  31. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997; 58 Suppl 7:37-40.
    View in: PubMed
    Score: 0.007
  32. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997; 33(4):755-60.
    View in: PubMed
    Score: 0.007
  33. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.007
  34. Does folic acid interfere with lamotrigine? Lancet Psychiatry. 2016 08; 3(8):704-705.
    View in: PubMed
    Score: 0.007
  35. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4.
    View in: PubMed
    Score: 0.007
  36. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41.
    View in: PubMed
    Score: 0.007
  37. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7.
    View in: PubMed
    Score: 0.007
  38. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995 Aug; 56(8):338-43.
    View in: PubMed
    Score: 0.007
  39. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37.
    View in: PubMed
    Score: 0.007
  40. Management of comorbid anxiety and depression. J Clin Psychiatry. 1995; 56 Suppl 2:10-3.
    View in: PubMed
    Score: 0.007
  41. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct; 71(10):1157-64.
    View in: PubMed
    Score: 0.006
  42. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63.
    View in: PubMed
    Score: 0.006
  43. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993 Oct; 54(10):380-4.
    View in: PubMed
    Score: 0.006
  44. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
    View in: PubMed
    Score: 0.006
  45. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
    View in: PubMed
    Score: 0.006
  46. Susceptibility to spontaneous MAOI hypertensive episodes. J Clin Psychiatry. 1991 Dec; 52(12):513-4.
    View in: PubMed
    Score: 0.005
  47. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991 Feb; 52(2):66-8.
    View in: PubMed
    Score: 0.005
  48. Antidepressant drug fever. J Clin Psychopharmacol. 1991 Feb; 11(1):73-4.
    View in: PubMed
    Score: 0.005
  49. Antidepressant combination and potentiation. Psychiatr Med. 1991; 9(1):55-75.
    View in: PubMed
    Score: 0.005
  50. Innovative somatic treatments for depression. Psychiatr Med. 1991; 9(1):77-103.
    View in: PubMed
    Score: 0.005
  51. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011 Jan; 45(1):64-75.
    View in: PubMed
    Score: 0.005
  52. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.005
  53. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990 Apr; 10(2):152-3.
    View in: PubMed
    Score: 0.005
  54. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
    View in: PubMed
    Score: 0.004
  55. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
    View in: PubMed
    Score: 0.004
  56. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.004
  57. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
    View in: PubMed
    Score: 0.004
  58. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007 May 15; 25(10):1163-74.
    View in: PubMed
    Score: 0.004
  59. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06.
    View in: PubMed
    Score: 0.004
  60. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry. 2006 Nov; 67(11):1674-81.
    View in: PubMed
    Score: 0.004
  61. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22.
    View in: PubMed
    Score: 0.003
  62. The Modified Rush Sexual Inventory: preliminary psychometric findings. Psychiatry Res. 2005 Dec 15; 137(3):175-81.
    View in: PubMed
    Score: 0.003
  63. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.003
  64. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 01; 58(5):347-54.
    View in: PubMed
    Score: 0.003
  65. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
    Score: 0.003
  66. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003 Oct 15; 54(8):806-17.
    View in: PubMed
    Score: 0.003
  67. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
    View in: PubMed
    Score: 0.003
  68. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
    View in: PubMed
    Score: 0.003
  69. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
    View in: PubMed
    Score: 0.003
  70. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
    View in: PubMed
    Score: 0.003
  71. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:32-41.
    View in: PubMed
    Score: 0.003
  72. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 Jun; 62(6):413-20.
    View in: PubMed
    Score: 0.003
  73. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan; 62(1):12-8.
    View in: PubMed
    Score: 0.002
  74. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
    View in: PubMed
    Score: 0.002
  75. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6.
    View in: PubMed
    Score: 0.002
  76. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53.
    View in: PubMed
    Score: 0.002
  77. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc. 1995 May; 1(3):291-6.
    View in: PubMed
    Score: 0.002
  78. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991 Apr; 11(2):127-32.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.